NCT00664703 - Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients | Biotech Hunter

Enrollment

13

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

Lobeline sulfate

Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.

DRUG

Methylphenidate HCl

Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.

DRUG

Placebo

Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.

Trial Locations (1)

40506

General Clinical Research Center, University of Kentucky, Lexington